Article in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
4 citing papers in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors at 4 institutions in 3 countries.
Nicole Ngo-Giang-HuongMaladies Infectieuses et Vecteurs: Écologie, Génétique, Évolution et Contrôle (MIVEGEC), Agropolis University Montpellier, Centre National de la Recherche Scientifique (CNRS), Institut de Recherche Pour le Développement (IRD), 34394 Montpellier, France.ORCID 0000-0001-8950-3234
Charline LeroiAssociated Medical Sciences (AMS)-PHPT Research Collaboration, Chiang Mai 50200, Thailand.
Dahlene FuscoDepartment of Medicine, Tulane University, 1430 Tulane Avenue, New Orleans, LA 70112, USA.
Tim R CresseyMaladies Infectieuses et Vecteurs: Écologie, Génétique, Évolution et Contrôle (MIVEGEC), Agropolis University Montpellier, Centre National de la Recherche Scientifique (CNRS), Institut de Recherche Pour le Développement (IRD), 34394 Montpellier, France.ORCID 0000-0002-8106-0974
Nantawan WangsaengMaladies Infectieuses et Vecteurs: Écologie, Génétique, Évolution et Contrôle (MIVEGEC), Agropolis University Montpellier, Centre National de la Recherche Scientifique (CNRS), Institut de Recherche Pour le Développement (IRD), 34394 Montpellier, France.
Nicolas SalvadoriMaladies Infectieuses et Vecteurs: Écologie, Génétique, Évolution et Contrôle (MIVEGEC), Agropolis University Montpellier, Centre National de la Recherche Scientifique (CNRS), Institut de Recherche Pour le Développement (IRD), 34394 Montpellier, France.ORCID 0000-0002-0820-5305
Natedao KongyaiDepartment of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, 110 Inthawaroros Road, Sripoom, Muang, Chiang Mai 50200, Thailand.ORCID 0000-0001-9658-4079
Wasna SirirungsiAssociated Medical Sciences (AMS)-PHPT Research Collaboration, Chiang Mai 50200, Thailand.
Marc LallemantAssociated Medical Sciences (AMS)-PHPT Research Collaboration, Chiang Mai 50200, Thailand.
Prasert AuewarakulDepartment of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkoknoi, Bangkok 10700, Thailand.ORCID 0000-0002-4745-4291
Woottichai KhamduangAssociated Medical Sciences (AMS)-PHPT Research Collaboration, Chiang Mai 50200, Thailand.ORCID 0000-0003-0196-5691
Gonzague JourdainMaladies Infectieuses et Vecteurs: Écologie, Génétique, Évolution et Contrôle (MIVEGEC), Agropolis University Montpellier, Centre National de la Recherche Scientifique (CNRS), Institut de Recherche Pour le Développement (IRD), 34394 Montpellier, France.ORCID 0000-0002-3365-7020
Centre National de la Recherche Scientifique · FRChiang Mai University · THSiriraj Hospital · THTulane University · US
Funding
NEVIRAPINE+ZIDOVUDINE--PREVENT PERINATAL HIV IN THAILANDR01HD039615 · NICHD · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI LALLEMANT, MARC J · 2000 to 2002
$3.7M
Standard zidovudine plus infant nevirapine to prevent perinatal HIV in ThailandR01HD052461 · NICHD · HARVARD SCHOOL OF PUBLIC HEALTH · PI LALLEMANT, MARC J · 2006 to 2010
$3.5M
Lopinavir/ritonavir + zidovudine to prevent perinatal HIV in ThailandR01HD056953 · NICHD · HARVARD SCHOOL OF PUBLIC HEALTH · PI LALLEMANT, MARC J · 2007 to 2013
$2.0M
Antiviral prophylaxis to prevent perinatal transmission of HBV in ThailandU01HD071889 · NICHD · INSTITUTE OF RESEARCH AND DEVELOPMENT · PI JOURDAIN, GONZAGUE JOSEPH · 2012 to 2016
Data about Zika virus infection and adverse pregnancy outcomes in Southeast Asia are scarce. We conducted an unmatched case-control study of Zika virus (ZIKV) serology in pregnant women enrolled in human immunodeficiency virus (HIV) or hepatitis B virus (HBV) perinatal prevention trials between 1997 and 2015 in Thailand. Case and control groups included women with and without adverse pregnancy outcomes. Plasma samples collected during the last trimester of pregnancy were tested for ZIKV IgG/IgM and Dengue IgG/IgM (Euroimmun, AG, Germany). Case newborn plasma samples were tested for ZIKV IgM and ZIKV RNA (Viasure, Spain). The case group included women with stillbirth (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Lack of Association between Adverse Pregnancy Outcomes and Zika Antibodies among Pregnant Women in Thailand between 1997 and 2015. · full record | OpenQuestion